Early stage HER2-negative breast cancer
Conditions
Interventions
Expert group with experience in treating early breast cancer:None
Group of physicians, chiefs, associate chiefs, and senior attending physicians in tertiary care hospitals with at least 5 years of experience in the treatment and research of early HER2-negative BC:No
Group of patients with early HER2-negative BC:None
Sponsors
Fudan University Shanghai Cancer Center
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Phase I (Qualitative Descriptive Study) Inclusion Criteria for HCPs: 1. Work in a tertiary hospital; 2. At least ten years of experience in the treatment and study of early HER2-negative BC; 3. Recruit doctors, chief doctors, deputy chief doctors and senior attending doctors; 4. Surgeons who have admitted >=10 newly diagnosed stage I~III, operable, HER-negative BC patients in the past 3 months, or who have admitted >=3 newly diagnosed stage I~III, operable, HER-negative BC patients in the past 3 months; 5. Signed paper or electronic informed consent for this study; 6. Participated in the formulation of BC-related guidelines or consensus in the past 2 years; 7. Possess membership in the National Cancer Society Breast Cancer or Tumor Committee. Phase II (Quantitative Survey Research) Inclusion Criteria for HCPs: 1. Work in a tertiary hospital; 2. At least 5 years of experience in treating and studying early HER2-negative BC; 3. Recruit doctors, chief doctors, deputy chief doctors and senior attending doctors; 4. Surgeons who have admitted >=10 newly diagnosed stage I~III, operable, HER-negative BC patients in the past 3 months, or who have admitted >=3 newly diagnosed stage I~III, operable, HER-negative BC patients in the past 3 months; 5. Signed paper or electronic informed consent for this study; 6. Possess membership in the Regional Cancer Association Breast Cancer or Tumor Committee. Inclusion criteria for patients with early-stage HER2-negative BC: 1.> = 18 years; 2. Histologically confirmed diagnosis of HER2-negative BC; 3. Pathological confirmed diagnosis of T1c N1-2 or T2-4 N0-2 (stage IIA~IIIB) BC; 4. Signed informed consent or verbal confirmation (electronic informed consent will be signed later) to participate in the study; 5. No more than 18 months from diagnosis to enrollment; 6. Patient is able to read and understand questionnaires written in the local language.
Exclusion criteria
Exclusion criteria: HCPs should be excluded if they have a conflict of interest with the early HER2-negative BC therapeutic agent used. Conflict of interest information will be collected through the subject's declaration. Patients will be excluded if they have an incomplete diagnostic pathology history, have other concurrent malignancies, or are unwilling to provide written informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Distribution of treatment modalities (surgery, preoperative neoadjuvant chemotherapy, preoperative neoadjuvant immunotherapy, preoperative neoadjuvant endocrine therapy, postoperative adjuvant chemotherapy, postoperative adjuvant immunotherapy, postoperative adjuvant endocrine therapy, postoperative follow-up, radiotherapy) in Chinese HER2-negative BC patients.; | — |
Secondary
| Measure | Time frame |
|---|---|
| Factors influencing decision-making on treatment modalities in Chinese HER2-negative BC patients;To investigate the factors influencing decision-making on treatment modalities for HER2-negative BC patients in China according to differences in hospitals, cities, or regions.; | — |
Countries
China
Contacts
Public ContactWu Jiong
Fudan University Shanghai Cancer Center
Outcome results
None listed